Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Fragile X syndrome: an update on developing treatment modalities.

Healy A, Rush R, Ocain T.

ACS Chem Neurosci. 2011 Aug 17;2(8):402-10. doi: 10.1021/cn200019z. Epub 2011 Mar 22. Review.

2.

Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics.

Robichaud AJ, Engers DW, Lindsley CW, Hopkins CR.

ACS Chem Neurosci. 2011 Aug 17;2(8):433-49. doi: 10.1021/cn200043e. Epub 2011 Jun 14. Review.

3.

Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.

Pacey LK, Tharmalingam S, Hampson DR.

J Pharmacol Exp Ther. 2011 Sep;338(3):897-905. doi: 10.1124/jpet.111.183327. Epub 2011 Jun 2.

4.

Fragile X syndrome and targeted treatment trials.

Hagerman R, Lauterborn J, Au J, Berry-Kravis E.

Results Probl Cell Differ. 2012;54:297-335. doi: 10.1007/978-3-642-21649-7_17. Review.

5.

Potential therapeutic interventions for fragile X syndrome.

Levenga J, de Vrij FM, Oostra BA, Willemsen R.

Trends Mol Med. 2010 Nov;16(11):516-27. doi: 10.1016/j.molmed.2010.08.005. Epub 2010 Sep 21. Review.

6.

Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond.

Gross C, Berry-Kravis EM, Bassell GJ.

Neuropsychopharmacology. 2012 Jan;37(1):178-95. doi: 10.1038/npp.2011.137. Epub 2011 Jul 27. Review.

7.

Mechanism-based approaches to treating fragile X.

Dölen G, Carpenter RL, Ocain TD, Bear MF.

Pharmacol Ther. 2010 Jul;127(1):78-93. doi: 10.1016/j.pharmthera.2010.02.008. Epub 2010 Mar 18. Review.

PMID:
20303363
8.

Courting a cure for fragile X.

Dölen G, Bear MF.

Neuron. 2005 Mar 3;45(5):642-4. Review.

9.

Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.

Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP.

Neuropharmacology. 2005 Dec;49(7):1053-66. Epub 2005 Jul 27.

PMID:
16054174
10.

Biomedical research. A fix for fragile X syndrome?

Miller G.

Science. 2006 Apr 28;312(5773):521. No abstract available.

PMID:
16645065
11.

The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice.

Vinueza Veloz MF, Buijsen RA, Willemsen R, Cupido A, Bosman LW, Koekkoek SK, Potters JW, Oostra BA, De Zeeuw CI.

Genes Brain Behav. 2012 Apr;11(3):325-31. doi: 10.1111/j.1601-183X.2011.00763.x. Epub 2012 Jan 19.

12.

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.

Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, Ramos FJ, Cornish K, He Y, Paulding C, Neri G, Chen F, Hadjikhani N, Martinet D, Meyer J, Beckmann JS, Delange K, Brun A, Bussy G, Gasparini F, Hilse T, Floesser A, Branson J, Bilbe G, Johns D, Gomez-Mancilla B.

Sci Transl Med. 2011 Jan 5;3(64):64ra1. doi: 10.1126/scitranslmed.3001708.

13.

Fragile X Syndrome and Alzheimer's Disease: Another story about APP and beta-amyloid.

Malter JS, Ray BC, Westmark PR, Westmark CJ.

Curr Alzheimer Res. 2010 May;7(3):200-6. Review.

14.

Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders.

Conn PJ, Lindsley CW, Meiler J, Niswender CM.

Nat Rev Drug Discov. 2014 Sep;13(9):692-708. doi: 10.1038/nrd4308. Review.

15.

Functional rescue of excitatory synaptic transmission in the developing hippocampus in Fmr1-KO mouse.

Meredith RM, de Jong R, Mansvelder HD.

Neurobiol Dis. 2011 Jan;41(1):104-10. doi: 10.1016/j.nbd.2010.08.026. Epub 2010 Sep 15.

PMID:
20817093
16.

Potential pharmacological treatment of fragile X syndrome during adulthood.

Xu ZH, Zhao MG.

Neurosci Bull. 2009 Oct;25(5):296-300. doi: 10.1007/s12264-009-0909-0. Review.

PMID:
19784085
17.

Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors.

Nakamoto M, Nalavadi V, Epstein MP, Narayanan U, Bassell GJ, Warren ST.

Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15537-42. Epub 2007 Sep 19.

18.

Advances in understanding fragile X syndrome and related disorders.

Rooms L, Kooy RF.

Curr Opin Pediatr. 2011 Dec;23(6):601-6. doi: 10.1097/MOP.0b013e32834c7f1a. Review.

PMID:
22001764
19.

Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.

Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, Jaeschke G, Bear MF, Lindemann L.

Neuron. 2012 Apr 12;74(1):49-56. doi: 10.1016/j.neuron.2012.03.009.

20.

The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome.

Hampson DR, Adusei DC, Pacey LK.

Biochem Pharmacol. 2011 May 1;81(9):1078-86. doi: 10.1016/j.bcp.2011.02.005. Epub 2011 Feb 17.

PMID:
21333634
Items per page

Supplemental Content

Write to the Help Desk